Evidence map›Paper›PMID 37941561›Full record

ArticleFrontiers in oncology2023

Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer.

Bikash Panthi, Rania M Mohamed, Beatriz E Adrada, Medine Boge, Rosalind P Candelaria, Huiqin Chen, Kelly K Hunt, Lei Huo, Ken-Pin Hwang, Anil Korkut and 19 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02276443 (ARTEMIS), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02276443 naactive not recruitingnot on this map

ARTEMIS: A Robust TNBC Evaluation FraMework to Improve Survival

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2015 to 2026Enrolled798ConditionsInvasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7ArmsChemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Lymph Node Biopsy, Ultrasonography
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 2 institutions in 2 countries.

Bikash PanthiDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Rania M MohamedDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Beatriz E AdradaDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Medine BogeDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Rosalind P CandelariaDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Huiqin ChenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Kelly K HuntDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Lei HuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ken-Pin HwangDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Anil KorkutDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Deanna L LaneDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Huong C Le-PetrossDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jessica W T LeungDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jennifer K LittonDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Sanaz PashapoorDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Frances PerezDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jong Bum SonDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jia SunDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Alastair ThompsonDepartment of Surgery, Baylor College of Medicine, Houston, TX, United States.
Debu TripathyDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Vicente ValeroDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Peng WeiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jason WhiteDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Zhan XuDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Wei YangDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Zijian ZhouDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Clinton YamDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Gaiane M Rauch *Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jingfei Ma *Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Early prediction of neoadjuvant systemic therapy (NAST) response for triple-negative breast cancer (TNBC) patients could help oncologists select individualized treatment and avoid toxic effects associated with ineffective therapy in patients unlikely to achieve pathologic complete response (pCR). The objective of this study is to evaluate the performance of radiomic features of the peritumoral and tumoral regions from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) acquired at different time points of NAST for early treatment response prediction in TNBC. This study included 163 Stage I-III patients with TNBC undergoing NAST as part of a prospective clinical trial (NCT02276443). Peritumoral and tumoral regions of interest were segmented on DCE images at baseline (BL) and after two (C2) and four (C4) cycles of NAST. Ten first-order (FO) radiomic features and 300 gray-level-co-occurrence matrix (GLCM) features were calculated. Area under the receiver operating characteristic curve (AUC) and Wilcoxon rank sum test were used to determine the most predictive features. Multivariate logistic regression models were used for performance assessment. Pearson correlation was used to assess intrareader and interreader variability. Seventy-eight patients (48%) had pCR (52 training, 26 testing), and 85 (52%) had non-pCR (57 training, 28 testing). Forty-six radiomic features had AUC at least 0.70, and 13 multivariate models had AUC at least 0.75 for training and testing sets. The Pearson correlation showed significant correlation between readers. In conclusion, Radiomic features from DCE-MRI are useful for differentiating pCR and non-pCR. Similarly, predictive radiomic models based on these features can improve early noninvasive treatment response prediction in TNBC patients undergoing NAST.

Indexed as

dynamic contrast-enhanced MRIneoadjuvant systemic therapypathologic complete responseradiomic analysistriple-negative breast cancer

Identifiers

PMID37941561
PMCPMC10628525
OpenAlexW4387938563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.